GlassScriptPhysician profile
Stefano Stella
NPI 1033114475
$1,679.33
in general payments reported to CMS, 2019-2025
30 companies · $103 in 2025
The $103 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $332 · 2020: $155 · 2021: $191 · 2022: $537 · 2023: $253 · 2024: $109 · 2025: $103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $371 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $370.77 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $351.72 | 2019-2023 | Lo Loestrin Fe, Orilissa |
| Merz North America, INC. | $317.84 | 2022 | |
| Astellas Pharma US INC | $162.30 | 2023-2024 | Veozah |
| Medtronic, INC. | $84.51 | 2021 | |
| Scynexis, INC. | $68.53 | 2022 | |
| Exact Sciences Corporation | $68.15 | 2024-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $63.65 | 2019-2025 | |
| Avanos Medical | $61.34 | 2020-2021 | |
| Lupin INC. | $45.81 | 2019-2020 | |
| Heron Therapeutics, INC. | $45.63 | 2023 | Zynrelef |
| Merck Sharp & Dohme LLC | $36.92 | 2019-2020 | |
| Hikma Pharmaceuticals USA | $36.01 | 2022 | |
| Davol INC. | $33.94 | 2021 | |
| Azurity Pharmaceuticals, INC. | $32.15 | 2023 | Adthyza |
| Avion Pharmaceuticals | $27.65 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $22.46 | 2019-2020 | |
| Organon LLC | $21.83 | 2024-2025 | Jada System |
| Dysis Medical, INC. | $19.85 | 2022 | |
| Sanara Medtech INC. | $18.84 | 2024 | Celleraterx |
| Mycovia Pharmaceuticals, INC. | $17.16 | 2023 | Vivjoa |
| Exeltis, USA INC. | $16.53 | 2025 | Slynd |
| Evofem Biosciences, INC. | $15.72 | 2025 | Phexxi, Solosec, Phexx |
| Meditrina | $15.11 | 2023 | |
| Agile Therapeutics, INC. | $14.47 | 2022 | |
| Pfizer INC. | $14.40 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $13.81 | 2022 | |
| Acella Pharmaceuticals, LLC | $13.66 | 2024 | NP Thyroid 60 |
| Therapeuticsmd, INC. | $13.63 | 2019 | |
| Mylan Pharmaceuticals INC. | $12.86 | 2021 | |
| Minerva Surgical, INC | $12.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stefano Stella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.